Scan to downloadＨｅａｒｔｓｅｅｄ株式会社 (219A) Earnings Releases & Disclosures
Upcoming
- 2026-11-13 Earnings Announcement
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-11-10 | — | Notice Regarding Designation of Allogeneic iPS Cell-Derived Cardiomyocyte Spheroids "HS-001" as a "SAKIGAKE Regenerative Medical Product" by the MHLW | |
| 2026-11-10 | — | Notice Regarding Designation of Allogeneic iPSC-Derived Cardiomyocyte Spheroids "HS-001" as an "Orphan Regenerative Medical Product" by the MHLW | |
| 2026-10-27 | — | Notice Regarding the First Patient Dosed in the Ischemic Heart Disease Cohort in the Phase I/II company-sponsored Clinical Trial of HS-005 | |
| 2026-09-17 | — | Notice on Resignation of Independent Board Director | |
| 2026-08-14 | Earnings Release | Non-consolidated Financial Results for the Six Months Ended June 30, 2026 (Under Japanese GAAP) | |
| 2026-08-14 | — | Notice Regarding Recording of Non-operating Income | |
| 2026-08-14 | — | Notice Concerning the Conclusion of a Special Overdraft Agreement |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.